Strategic Partnership for Lung Cancer Innovations
Biofidelity and CellCarta have announced an exciting partnership aimed at deploying Biofidelity's innovative Aspyre® Lung in global clinical trials. This collaboration represents a significant advancement in genomic solutions for lung cancer diagnostics and therapy, particularly for non-small cell lung cancer (NSCLC).
Aspyre Lung: Revolutionizing Cancer Detection
Aspyre Lung stands out for its capability in detecting established NSCLC biomarkers through a streamlined and efficient four-step workflow. It analyzes DNA and RNA derived from both tissue and blood samples and is compatible with existing qPCR platforms, ensuring easy integration into laboratories worldwide. This capability aligns seamlessly with CellCarta's mission to enhance global clinical trials through cutting-edge genomic services.
Global Implementation of Aspyre Lung
As part of the strategic agreement, CellCarta will initially set up and validate the Aspyre Lung system within their European laboratories, progressing to their facilities in the United States. This partnership grants CellCarta non-exclusive rights to utilize the Aspyre Lung technology for clinical trials on a global scale, thus ensuring reliable and rapid enrollment for trial participants using both liquid and tissue biopsies.
Quotes from Leadership
“We are thrilled to form this strategic alliance with CellCarta to expand the reach of Aspyre Lung into global clinical research,” stated Barnaby Balmforth, Co-Founder and CEO of Biofidelity. “At Biofidelity, our vision is to democratize access to the life-altering benefits of genomics. By partnering with CellCarta, we aim to enhance the efficiency of clinical trial enrollment through simplified genomic profiling with Aspyre Lung, significantly advancing our mission.”
CellCarta’s CEO, Dusty Tenney, expressed enthusiasm for this collaboration, stating, “Partnering with Biofidelity allows us to expand our extensive portfolio of biomarker testing services. The integration of Aspyre Lung into our laboratory services signifies a vital step in propelling precision medicine forward.”
Enhancing Clinical Trial Efficiency
This partnership is particularly timely considering the increasing demand for precision medicine in oncology. By leveraging Biofidelity's technology through the robust infrastructure of CellCarta's CRO capabilities, the two companies are poised to redefine clinical trial dynamics. This collaboration underscores their commitment to patient-centric solutions and accelerated drug development.
About Biofidelity
Biofidelity is a rapidly expanding genomic technology firm dedicated to improving cancer treatment outcomes. The company focuses on facilitating better-targeted therapies, early detection of resistance to treatment, and ongoing monitoring of treatment responses. Their innovative solutions serve to extend and enhance the lives of cancer patients.
About CellCarta
CellCarta is a prominent global CRO that specializes in laboratory services for the biopharmaceutical sector. Possessing CAP accreditations and CLIA certifications for several testing methods, CellCarta operates across multiple countries and offers a comprehensive suite of biomarker testing services tailored to meet the unique requirements of pharmaceutical firms. Their expertise in immunology, histopathology, and genomics supports the full spectrum of drug development from initial discovery through to late-stage clinical trials.
Frequently Asked Questions
What is the main focus of the Biofidelity and CellCarta partnership?
The main focus is to deploy the Aspyre® Lung technology in global clinical trials to enhance genomic solutions for lung cancer diagnosis and treatment.
How does Aspyre Lung work?
Aspyre Lung simplifies the detection of NSCLC biomarkers by analyzing both DNA and RNA from tissue and blood through a four-step workflow.
What benefits does this partnership provide for clinical trials?
This partnership offers revolutionary services that improve clinical trial enrollment through the use of liquid and tissue biopsy samples.
Who are the key leaders involved in this partnership?
The key leaders are Barnaby Balmforth, Co-Founder and CEO of Biofidelity, and Dusty Tenney, CEO of CellCarta.
What is the mission of Biofidelity?
Biofidelity's mission is to enhance access to genomic solutions that significantly improve the lives of cancer patients through better-targeted therapies and timely monitoring.
